For Q4FY26, revenue surged by 18.2% to ₹684.8 crore, compared to ₹579.5 crore in the corresponding quarter of the previous year. Earnings before interest, tax, depreciation, and amortization (EBITDA) rose by 11% year-on-year, amounting to ₹77.2 crore, up from ₹69.5 crore. The EBITDA margin remained stable at 12% year-on-year.
The company announced a final dividend of 25% (₹0.50 per equity share of face value ₹2) for FY26, pending shareholder approval. This dividend will be paid or dispatched within 10 working days following the upcoming annual general meeting, with the record date to be announced later.
ALSO READ |
Rossari Biotech promoters are considering a stake sale amid early-stage interest: Exclusive
The company stated that its capacity expansion plan is being reviewed in light of changing business needs and market conditions. The planned investment will now proceed in phases over the next two years, while the overarching strategic goal of the expansion remains intact.
Rossari Biotech has established a new research and development facility in Navi Mumbai. Additionally, the company will be moving its existing R&D facility from IIT Bombay to the new site. This new R&D center is part of its capital expenditure strategy aimed at enhancing innovation, product development, and technological capabilities.
In a separate announcement, the company appointed Udeypaul Singh Gill as an additional director in the category of non-executive independent director for a three-year term, from April 28, 2026, to April 27, 2029, pending shareholder approval and based on the Nomination and Remuneration Committee’s recommendation.
ALSO READ | Rossari Biotech anticipates growth in exports, plans to exit low-margin businesses
Shares of Rossari Biotech Ltd closed at ₹506.15, down by ₹10.05, or 1.95%, on the BSE today, April 27.
(Edited by : Shoma Bhattacharjee)
First Published: Apr 27, 2026 6:19 PM IST
